Floatz logo

SOLIFENACIN

Overactive Bladder

VA Office of Research and DevelopmentSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Overactive Bladder cohort.

Asset / SponsorPhaseRating
Mirabegron
VA Office of Research and Development
Phase 4BB
TROSPIUM
Allergan
Phase 4BB
Nabiximols
Jazz Pharmaceuticals
Phase 3BB
Oxybutynin
University of California, Davis
Phase 3B
Fesoterodine
Sir Mortimer B. Davis - Jewish General Hospital
Phase 4B

View all 22 →

Same molecule, other indications

SOLIFENACIN is also rated in:

overactive bladderDormant
B
Indicative ·
58 / 100
View asset →
Spinal Cord DiseasesDormant
B
Indicative ·
58 / 100
View asset →
cognitive disorderDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →